cGKIα/β Antibody (E-1): sc-271765
- cGKIα/β Antibody (E-1) is a mouse monoclonal IgG1 κ cGKIα/β antibody, cited in 1 publications, provided at 200 µg/ml
- raised against amino acids 191-290 mapping within an internal region of cGKIα/β of human origin
- recommended for detection of cGKIα/β of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for cGKIα/β Antibody (E-1) for WB applications. These reagents are now offered in bundles with cGKIα/β Antibody (E-1) (see ordering information below).
cGKIα/β Antibody (E-1) is a mouse monoclonal IgG1 kappa light chain antibody that detects cGKI alpha / beta protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). anti-cGKI alpha / beta antibody (E-1) is available as the non-conjugated form. cGKI protein, also known as PRKG1, plays a crucial role in regulating vascular smooth muscle relaxation by lowering intracellular calcium levels, which is vital for maintaining proper blood flow and pressure. cGKI exists in two isoforms, α and β, which differ in their N-terminal sequences but share a common function in phosphorylating target proteins. cGKI includes one protein kinase domain, one AGC-kinase C-terminal domain, and two cyclic nucleotide-binding domains, which are essential for enzymatic activity and interaction with cyclic GMP. cGKI interacts with various signaling pathways, influencing numerous physiological processes, including smooth muscle contraction and neuronal signaling. Understanding cGKI structure and function is important for elucidating its role in cardiovascular health and potential therapeutic targets for related diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
cGKIα/β Antibody (E-1) References:
- cGMP-mediated signaling via cGKIalpha is required for the guidance and connectivity of sensory axons. | Schmidt, H., et al. 2002. J Cell Biol. 159: 489-98. PMID: 12417579
- Distribution of IRAG and cGKI-isoforms in murine tissues. | Geiselhöringer, A., et al. 2004. FEBS Lett. 575: 19-22. PMID: 15388327
- Role of smooth muscle cGMP/cGKI signaling in murine vascular restenosis. | Lukowski, R., et al. 2008. Arterioscler Thromb Vasc Biol. 28: 1244-50. PMID: 18420996
- Anemia and splenomegaly in cGKI-deficient mice. | Föller, M., et al. 2008. Proc Natl Acad Sci U S A. 105: 6771-6. PMID: 18443297
- Calcium-dependent and calcium-independent inhibition of contraction by cGMP/cGKI in intestinal smooth muscle. | Frei, E., et al. 2009. Am J Physiol Gastrointest Liver Physiol. 297: G834-9. PMID: 19628652
- The tumor suppressor p53 transcriptionally regulates cGKI expression during neuronal maturation and is required for cGMP-dependent growth cone collapse. | Tedeschi, A., et al. 2009. J Neurosci. 29: 15155-60. PMID: 19955367
- Kinetics of relaxation by cGMP/cGKI signaling in fundus smooth muscle. | Ertl, C., et al. 2011. Eur J Pharmacol. 670: 266-71. PMID: 21914444
- The role of cGMP/cGKI signalling and Trpc channels in regulation of vascular tone. | Loga, F., et al. 2013. Cardiovasc Res. 100: 280-7. PMID: 23832809
- cGMP-dependent protein kinase I (cGKI) modulates human hepatic stellate cell activation. | Franko, A., et al. 2018. Metabolism. 88: 22-30. PMID: 30195474
- Targets of cGMP/cGKI in Cardiac Myocytes. | Adler, J., et al. 2020. J Cardiovasc Pharmacol. 75: 494-507. PMID: 32168155
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
cGKIα/β Antibody (E-1) | sc-271765 | 200 µg/ml | $316.00 | |||
cGKIα/β Antibody (E-1): m-IgG Fc BP-HRP Bundle | sc-540262 | 200 µg Ab; 10 µg BP | $354.00 | |||
cGKIα/β Antibody (E-1): m-IgG1 BP-HRP Bundle | sc-542009 | 200 µg Ab; 20 µg BP | $354.00 |